JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth

British Journal of Haematology

Volumn 160, Issue 2, 2013, Pages 177-187

  Griner, Lori N ^a   Mcgraw, Kathy L ^a   Johnson, Joseph O ^a   List, Alan F ^a   Reuther, Gary W ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cholesterol; JAK2 V617F; Lipid raft; Myeloproliferative neoplasms; Statin

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; SIMVASTATIN; VALINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME LOCALIZATION; ERYTHROID CELL; HUMAN; HUMAN CELL; LIPID RAFT; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; CELLS, CULTURED; CHOLESTEROL; COLONY-FORMING UNITS ASSAY; DRUG EVALUATION, PRECLINICAL; ERYTHROID PRECURSOR CELLS; HUMANS; JANUS KINASE 2; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MEGAKARYOCYTE PROGENITOR CELLS; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; POINT MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SIMVASTATIN; STAT5 TRANSCRIPTION FACTOR;

EID: 84872269144     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12103     Document Type: Article

References (54)

1. Allen, J.A., Halverson-Tamboli, R.A. & Rasenick, M.M. (2007) Lipid raft microdomains and neurotransmitter signalling. Nature Reviews Neuroscience, 8, 128-140.
2. Anderson, R.G. & Jacobson, K. (2002) A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science, 296, 1821-1825.
3. Awasthi-Kalia, M., Schnetkamp, P.P. & Deans, J.P. (2001) Differential effects of filipin and methyl-beta-cyclodextrin on B cell receptor signaling. Biochemical and Biophysical Research Communications, 287, 77-82.
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
5. Brown, D.A. (2006) Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology, 21, 430-439.
6. Dai, Y., Khanna, P., Chen, S., Pei, X.Y., Dent, P. & Grant, S. (2007) Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood, 109, 4415-4423.
7. Dawson, M.A., Bannister, A.J., Gottgens, B., Foster, S.D., Bartke, T., Green, A.R. & Kouzarides, T. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 461, 819-822.
8. Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E. & Lippman, S.M. (2005) Statins and cancer prevention. Nature Reviews Cancer, 5, 930-942.
9. Dimitroulakos, J., Nohynek, D., Backway, K.L., Hedley, D.W., Yeger, H., Freedman, M.H., Minden, M.D. & Penn, L.Z. (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood, 93, 1308-1318.
10. Edidin, M. (2001) Shrinking patches and slippery rafts: scales of domains in the plasma membrane. Trends in Cell Biology, 11, 492-496.
11. Ferro, D., Parrotto, S., Basili, S., Alessandri, C. & Violi, F. (2000) Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. Journal of the American College of Cardiology, 36, 427431.
12. Fleischman, A.G., Aichberger, K.J., Luty, S.B., Bumm, T.G., Petersen, C.L., Doratotaj, S., Vasudevan, K.B., LaTocha, D.H., Yang, F., Press, R.D., Loriaux, M.M., Pahl, H.L., Silver, R.T., Agarwal, A., O'Hare, T., Druker, B.J., Bagby, G.C. & Deininger, M.W. (2011) TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118, 6392-6398.
13. Frederiksen, H., Farkas, D.K., Christiansen, C.F., Hasselbalch, H.C. & Sorensen, H.T. (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood, 118, 6515-6520.
14. Galbiati, F., Razani, B. & Lisanti, M.P. (2001) Emerging themes in lipid rafts and caveolae. Cell, 106, 403-411.
15. Hamadmad, S.N. & Hohl, R.J. (2007) Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochemical Pharmacology, 74, 590-600.
16. Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.U., Superti-Furga, G. & Sexl, V. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature Chemical Biology, 8, 285-293.
17. Harder, T. & Simons, K. (1997) Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Current Opinion in Cell Biology, 9, 534-542.
18. Hasselbalch, H.C. (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood, 119, 3219-3225.
19. Hasselbalch, H.C. & Riley, C.H. (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leukemia Research, 30, 1217-1225.
20. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
21. Jatiani, S.S., Baker, S.J., Silverman, L.R. & Reddy, E.P. (2010) Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes and Cancer, 1, 979-993.
22. Jedidi, A., Marty, C., Oligo, C., Jeanson-Leh, L., Ribeil, J.A., Casadevall, N., Galy, A., Vainchenker, W. & Villeval, J.L. (2009) Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood, 114, 1842-1851.
23. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
24. Kurzchalia, T.V. & Parton, R.G. (1999) Membrane microdomains and caveolae. Current Opinion in Cell Biology, 11, 424-431.
25. Lee, T.S., Ma, W., Zhang, X., Giles, F., Kantarjian, H. & Albitar, M. (2009) Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer, 115, 1692-1700.
26. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
27. Levine, R.L., Pardanani, A., Tefferi, A. & Gilliland, D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer, 7, 673-683.
28. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G. & Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences USA, 102, 18962-18967.
29. Lu, X., Huang, L.J. & Lodish, H.F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. The Journal of Biological Chemistry, 283, 5258-5266.
30. McGraw, K.L., Fuhler, G.M., Johnson, J.O., Clark, J.A., Caceres, G.C., Sokol, L. & List, A.F. (2012) Erythropoietin receptor signaling is membrane raft dependent. PLoS ONE, 7, e34477.
31. Monastyrskaya, K., Hostettler, A., Buergi, S. & Draeger, A. (2005) The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. The Journal of Biological Chemistry, 280, 71357146.
32. Newman, A., Clutterbuck, R.D., Powles, R.L., Catovsky, D. & Millar, J.L. (1997) A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leukemia & Lymphoma, 24, 533-537.
33. Oh, S.T. & Gotlib, J. (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology, 3, 323-337.
34. Ostermeyer, A.G., Beckrich, B.T., Ivarson, K.A., Grove, K.E. & Brown, D.A. (1999) Glycosphingolipids are not essential for formation of detergent-resistant membrane rafts in melanoma cells. methyl-beta-cyclodextrin does not affect cell surface transport of a GPI-anchored protein. The Journal of Biological Chemistry, 274, 34459-34466.
35. Pardanani, A., Vannucchi, A.M., Passamonti, F., Cervantes, F., Barbui, T. & Tefferi, A. (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia, 25, 218-225.
36. Pralle, A., Keller, P., Florin, E.L., Simons, K. & Horber, J.K. (2000) Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. Journal of Cell Biology, 148, 997-1008.
37. Prchal, J.F. & Axelrad, A.A. (1974) Letter: bone-marrow responses in polycythemia vera. The New England Journal of Medicine, 290, 1382.
38. Quentmeier, H., MacLeod, R.A., Zaborski, M. & Drexler, H.G. (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia, 20, 471-476.
39. Rinaldi, C.R., Rinaldi, P., Alagia, A., Gemei, M., Esposito, N., Formiggini, F., Martinelli, V., Senyuk, V., Nucifora, G. & Pane, F. (2010) Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood, 116, 6023-6026.
40. Scheiffele, P., Rietveld, A., Wilk, T. & Simons, K. (1999) Influenza viruses select ordered lipid domains during budding from the plasma membrane. The Journal of Biological Chemistry, 274, 2038-2044.
41. Scherber, R. & Mesa, R.A. (2011) Future therapies for the myeloproliferative neoplasms. Current Hematologic Malignancy Reports, 6, 22-27.
42. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459-468.
43. Sehgal, P.B. (2003) Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochimica Polonica, 50, 583-594.
44. Simons, K. & Ikonen, E. (1997) Functional rafts in cell membranes. Nature, 387, 569-572.
45. Simons, K. & Toomre, D. (2000) Lipid rafts and signal transduction. Nature Reviews Molecular Cell Biology, 1, 31-39.
46. Tefferi, A. (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 119, 2721-2730.
47. Vannucchi, A.M., Masala, G., Antonioli, E., Chiara Susini, M., Guglielmelli, P., Pieri, L., Maggi, L., Caini, S., Palli, D., Bogani, C., Ponziani, V., Pancrazzi, A., Annunziato, F. & Bosi, A. (2009) Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiology Biomarkers and Prevention, 18, 2068-2073.
48. Waheed, A.A. & Freed, E.O. (2009) Lipids and membrane microdomains in HIV1 replication. Virus Research, 143, 162-176.
49. Walz, C., Crowley, B.J., Hudon, H.E., Gramlich, J.L., Neuberg, D.S., Podar, K., Griffin, J.D. & Sattler, M. (2006) Activated Jak2 with the V617F point mutation promotes G1/S phase transition. The Journal of Biological Chemistry, 281, 18177-18183.
50. Weng, T.C., Yang, Y.H., Lin, S.J. & Tai, S.H. (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics, 35, 139-151.
51. Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Yi, T., Tang, B., Miura, O. & Ihle, J.N. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 74, 227-236.
52. Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M.B., Smithgall, T.E. & Arlinghaus, R.B. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene, 20, 6188-6195.
53. Yvan-Charvet, L., Pagler, T., Gautier, E.L., Avagyan, S., Siry, R.L., Han, S., Welch, C.L., Wang, N., Randolph, G.J., Snoeck, H.W. & Tall, A.R. (2010) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science, 328, 1689-1693.
54. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. The Journal of Biological Chemistry, 280, 22788-22792.